This approach also improved HPP-related defects in the cementum, enamel, and dentin.20, 22, 24 Therefore, it is expected that the combination of scAAV8-MCK-TNALP-D10 gene therapy and ERT will have further therapeutic effects on the bones and teeth of HPP patients, thereby decreasing both the frequency of ERT administration and its inherent burdens on these patients. This evidence concerns the gene ALPL and hypophosphatasia.